A polymer coating applied to Salmonella prevents the binding of Salmonella-specific antibodies

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages 717-725

  Lee, Che Hsin ^a   Lin, Yu Hsin ^b   Hsieh, Jeng Long ^c   Chen, Man Chin ^a   Kuo, Wan Lin ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

neutralizing antibody; poly(allylamine hydrochloride); Salmonella; tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIUM ANTIBODY; NEUTRALIZING ANTIBODY; POLY(ALLYLAMINE HYDROCHLORIDE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; FEMALE; GENE TRANSFER; IMMUNIZATION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE MIGRATION; MALIGNANT NEOPLASTIC DISEASE; MICROBIAL ACTIVITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; SEROTYPE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; FEMALE; IMMUNIZATION; MACROPHAGES; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEUTROPHILS; POLYMERS; SALMONELLA ENTERICA;

EID: 84870251971     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27700     Document Type: Article

References (34)

1. Pawelek JM, Low KB, Bermudes D,. Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4: 548-56.
2. Pawelek JM, Low KB, Bermudes D,. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57: 4537-44.
3. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-60.
4. Lee CH, Wu CL, Shiau AL,. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2004; 6: 1382-93.
5. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17: 37-41.
6. Saccheri F, Pozzi C, Avogadri F, et al. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med 2010; 2: 44ra57.
7. Shiau AL, Chen CC, Yo YT, et al. Enhancement of humoral and cellular immune responses by an oral Salmonella choleraesuis vaccine expressing porcine prothymosin α. Vaccine 2005; 23: 5563-71.
8. Lee CH, Wu CL, Tai YS, et al. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol Ther 2005; 11: 707-16.
9. Lee CH, Wu CL, Chen SH, et al. Humoral immune responses inhibit the antitumor activities mediated by Salmonella enterica serovar choleraesuis. J Immunother 2009; 32: 376-88.
10. Graham SM,. Salmonellosis in children in developing and developed countries and populations. Curr Opin Infect Dis 2002; 15: 507-12.
11. Harris TJ, Green JJ, Fung PW, et al. Tissue-specific gene delivery via nanoparticle coating. Biomaterials 2010; 31: 998-1006.
12. Fakhrullin RF, Zamaleeva AI, Morozov MV, et al. Living fungi cells encapsulated in polyelectrolyte shells doped with metal nanoparticles. Langmuir 2009; 25: 4628-34.
13. Kahraman M, Zamaleeva AI, Fakhrullin RF, et al. Layer-by-layer coating of bacteria with noble metal nanoparticles for surface-enhanced Raman scattering. Anal Bioanal Chem 2009; 395: 2559-67.
14. pos cells in a mouse model of breast cancer. Cancer Lett 2010; 287: 172-81.
15. Chang CH, Huang WY, Lai CH, et al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori. Acta Biomater 2011; 7: 593-603.
16. Lee CH, Wu CL, Shiau AL,. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 2005; 12: 175-82.
17. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20: 142-52.
18. Lee CH, Wu CL, Shiau AL,. Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer 2008; 122: 930-35.
19. Avogadri F, Mittal D, Saccheri F, et al. Intra-tumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. Eur J Immunol 2008; 38: 1937-47.
20. Lee CH, Wu CL, Shiau AL,. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res 2008; 14: 1905-12.
21. Lee CH, Hsieh JL, Wu CL, et al. T cell augments the antitumor activity of tumor-targeting Salmonella. Appl Microbiol Biotechnol 2011; 90: 1381-8.
22. Liu F, Zhang L, Hoffman RM, et al. Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle 2010; 9: 4518-24.
23. Nagakura C, Hayashi K, Zhao M, et al. Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res 2009; 29: 1873-8.
24. Yam C, Zhao M, Hayashi K, et al. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 2010; 164: 248-55.
25. Hayashi K, Zhao M, Yamauchi K, et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle 2009; 8: 870-5.
26. Kimura H, Zhang L, Zhao M, et al. Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif 2010; 43: 41-8.
27. Hayashi K, Zhao M, Yamauchi K, et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 2009; 106: 992-8.
28. Zhao M, Geller J, Ma H, et al. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 2007; 104: 10170-4.
29. Zhao M, Yang M, Ma H, et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006; 66: 7647-52.
30. Lee CH,. Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. Appl Microbiol Biotechnol 2012; 93: 517-23.
31. Avogadri F, Martinoli C, Petrovska L, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 2005; 65: 3920-7.
32. Kasai S, Fujimoto S, Nitta K, et al. Antitumor activity of polymorphonuclear leukocytes activated by a β-1,3-D-glucan. J Pharmacobiodyn 1991; 14: 519-25.
33. Fujii Y, Kimura S, Arai S, et al. In vivo antitumor effect of lymphokine-activated rodent polymorphonuclear leukocytes. Cancer Res 1987; 47: 6000-5.
34. Yang KD, Stone RM, Lee CS, et al. Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother 1992; 35: 277-82.